Stephanie Braun
Head, Medical Affairs US Oncology Astellas Pharma
Seminars
Tuesday 8th September 2026
Degrading the Undruggable: A New Paradigm for Targeting KRAS
3:00 pm
- Mechanism of Action of a Novel KRAS G12d Targeted Protein Degrader: Setidegrasib
- Clinical Overview: Efficacy and Safety in PDAC, NSCLC and other solid tumors
- Future Directions
